Eton O, Bajorin D F, Chapman P B, Cody B V, Houghton A N
Division of Solid Tumor Oncology, Memorial-Sloan Kettering Cancer Center, New York, NY.
Invest New Drugs. 1991 Feb;9(1):101-3. doi: 10.1007/BF00194558.
Fourteen patients with metastatic melanoma were treated with cisplatin and etoposide by bolus intravenous infusion daily for 5 consecutive days each month. All patients were evaluable for toxicity and twelve for response. Eight patients were treated with cisplatin 20 mg/m2 and etoposide 100 mg/m2 daily. Because of excessive myelosuppression, the daily dose of etoposide was reduced to 75 mg/m2 in the remaining six patients. There were no major responses among 12 evaluable patients (major response rate less than or equal to 24% with 95% confidence). The median time to progression was one month. One patient with a liver metastasis had a minor response lasting 6+ months. The combination of cisplatin and etoposide in these doses and schedule lacked sufficient clinical efficacy in the treatment of metastatic melanoma.
14例转移性黑色素瘤患者接受顺铂和依托泊苷治疗，每月连续5天每日静脉推注给药。所有患者均可评估毒性，12例可评估疗效。8例患者每日接受顺铂20mg/m²和依托泊苷100mg/m²治疗。由于骨髓抑制过度，其余6例患者的依托泊苷每日剂量减至75mg/m²。12例可评估患者中无主要缓解（主要缓解率小于或等于24%，95%置信区间）。疾病进展的中位时间为1个月。1例肝转移患者有轻微缓解，持续6个多月。这些剂量和给药方案的顺铂和依托泊苷联合用药在转移性黑色素瘤治疗中缺乏足够的临床疗效。
